Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

December 5, 2024 UCBN News, Syndication Comments Off on Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with another company. This warning letter is unrelated to any Edgewise clinical trial or data. None of the
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Maia Closes Seed Round to Accelerate AI-Powered Medical Coding and Revenue Cycle Management for Orthopaedic Practices

June 16, 2026 UCBN News, Syndication Comments Off on Maia Closes Seed Round to Accelerate AI-Powered Medical Coding and Revenue Cycle Management for Orthopaedic Practices

LITTLETON, Colo., June 16, 2026 /PRNewswire/ — Maia, the AI-powered medical coding and revenue cycle management (RCM) platform purpose-built for orthopaedic practices, today announced the close of its seed financing round of $1.2 million. The […]